Terminated PHASE2 INTERVENTIONAL 3-arm NCT02147990

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Sponsor: Clovis Oncology, Inc.

Conditions Non-small Cell Lung Cancer

Interventions Rociletinib

Updated 13 times since 2017 Last updated: Jul 28, 2020 Started: Jun 16, 2014 Primary completion: Jul 30, 2019 Completion: Aug 27, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor discontinued development of CO-1686 for NSCLC.

Other terminated trials from Clovis Oncology, Inc.

More terminations from Clovis Oncology, Inc.

Other Non-small Cell Lung Cancer trials with similar outcome

Browse all Non-small Cell Lung Cancer trials

Listed as NCT02147990, this PHASE2 trial focuses on Non-small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Clovis Oncology, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 8 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2
Sep 2020 — Jan 2021 [monthly]

Terminated PHASE2
Nov 2019 — Sep 2020 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Oct 2018 — Nov 2019 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting
Jun 2018 — Oct 2018 [monthly]

Unknown Status PHASE2
Oct 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Feb 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clovis Oncology, Inc.

Data source: Clovis Oncology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alhambra, United States , Amarillo, United States , Amsterdam, Netherlands , Arlington, United States , Austin, United States , Badalona, Spain , Bakersfield, United States , Barcelona, Spain , Beaumont, United States , Bedford, United States and 67 more locations